BETA BIONICS ($BBNX) posted quarterly earnings results on Tuesday, July 29th. The company reported earnings of -$0.39 per share, beating estimates of -$0.46 by $0.07. The company also reported revenue of $23,240,000, beating estimates of $20,077,567 by $3,162,433.
You can see Quiver Quantitative's $BBNX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BETA BIONICS Insider Trading Activity
BETA BIONICS insiders have traded $BBNX stock on the open market 18 times in the past 6 months. Of those trades, 2 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $BBNX stock by insiders over the last 6 months:
- HADLEY HARBOR AGGREGATOR IV, L.P. WELLINGTON purchased 1,000,000 shares for an estimated $17,000,000
- MIKE MENSINGER (Chief Product Officer) has made 1 purchase buying 33,350 shares for an estimated $566,950 and 4 sales selling 1,128 shares for an estimated $20,168.
- SEAN SAINT (President & CEO) has made 0 purchases and 3 sales selling 3,439 shares for an estimated $61,525.
- STEPHEN FEIDER (Chief Financial Officer) has made 0 purchases and 3 sales selling 1,497 shares for an estimated $26,783.
- STEVEN JON RUSSELL (Chief Medical Officer) has made 0 purchases and 3 sales selling 1,039 shares for an estimated $18,588.
- MARK HOPMAN (Chief Commercial Officer) has made 0 purchases and 3 sales selling 868 shares for an estimated $15,529.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BETA BIONICS Analyst Ratings
Wall Street analysts have issued reports on $BBNX in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 06/16/2025
- Lake Street issued a "Buy" rating on 06/12/2025
- Wolfe Research issued a "Outperform" rating on 05/30/2025
- Stifel issued a "Buy" rating on 02/24/2025
- Piper Sandler issued a "Overweight" rating on 02/24/2025
- Leerink Partners issued a "Outperform" rating on 02/24/2025
- Ladenburg Thalmann issued a "Buy" rating on 02/20/2025
To track analyst ratings and price targets for BETA BIONICS, check out Quiver Quantitative's $BBNX forecast page.
BETA BIONICS Price Targets
Multiple analysts have issued price targets for $BBNX recently. We have seen 10 analysts offer price targets for $BBNX in the last 6 months, with a median target of $26.0.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $26.0 on 06/16/2025
- Frank Takkinen from Lake Street set a target price of $30.0 on 06/12/2025
- David Roman from Goldman Sachs set a target price of $16.0 on 05/30/2025
- Mike Polark from Wolfe Research set a target price of $20.0 on 05/30/2025
- Mathew Blackman from Stifel set a target price of $25.0 on 02/24/2025
- Matt O'Brien from Piper Sandler set a target price of $26.0 on 02/24/2025
- Mike Kratky from Leerink Partners set a target price of $28.0 on 02/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
